We owe so much to clinical trials and particularly to those who participate in them, the pandemic has made all of us intimately more aware of their value. At Symplur, we’re going to shine the light on trials as it relates to our conversational datasets. We’re starting this journey by creating a new healthcare stakeholder label named “Investigator”. All HCPs, researchers and academics who are currently or have been a principal or co-investigator of a clinical trial will now be highlighted in Symplur, which allows for some new use cases and questions to be answered, such as:
- Who are the clinical trial investigators with high impact voices in pancreatic cancer conversations?
- What do professional investigators say about a certain trial result and design?
- Are there any clinical trial investigators that interact with lung cancer patient advocates?